ArticleClinical and experimental nephrology2012
Cost-effectiveness of chronic kidney disease mass screening test in Japan.
Article in Clinical and experimental nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Screening for chronic kidney disease: a systematic review of emerging evidence and perspectives.Renal failure · 2025Pooled it
- Maintenance Dialysis throughout the World in Years 1990 and 2010.Journal of the American Society of Nephrology : JASN · 2015Pooled it
- Methods Used in Economic Evaluations of Chronic Kidney Disease Testing - A Systematic Review.PloS one · 2015Pooled it
- Beyond urinalysis: a review of life-course chronic kidney disease screening across health examination systems in Japan.Clinical and experimental nephrology · 2026Review
- Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan.Clinical and experimental nephrology · 2026Article
- Evidence-practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records.Clinical and experimental nephrology · 2026Observational
- Trajectories of kidney function over 10 years in patients with chronic kidney disease: a 10 year follow-up of FROM-J study.Clinical and experimental nephrology · 2026Article
- Efficacy of screening with dipstick urinalysis in predicting renal function decline in healthy workers: a 10-year follow-up study.Clinical and experimental nephrology · 2025Article
- Using Risk Assessment to Improve Screening for Albuminuria among US Adults without Diabetes.Journal of general internal medicine · 2025Article
- Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand.Health economics review · 2025Article
- Association between proteinuria changes and colorectal cancer incidence: evidence from a nationwide cohort study.BMC gastroenterology · 2025Article
- Prevalence of diabetes mellitus and dialysis risk based on annual health checkup frequency among National Health Insurance citizens in Japan.BMC public health · 2025Article
- Economic burden of inpatient hospitalizations for pediatric chronic kidney disease in the US.Pediatric nephrology (Berlin, Germany) · 2025Article
- Inside CKD: Cost-Effectiveness of Multinational Screening for CKD.Kidney international reports · 2025Article
- Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study.The Lancet regional health. Western Pacific · 2025Article
- Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- The Clinical and Economic Burden of Chronic Kidney Disease in Poland: Inside Patient-Level Microsimulation Modelling of CKD.Journal of clinical medicine · 2024Article
- Examining chronic kidney disease screening frequency among diabetics: a POMDP approach.Health care management science · 2024Article
- Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study.Health technology assessment (Winchester, England) · 2024Article
- Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review.Clinical kidney journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a significant public health problem. Strategy for its early detection is still controversial. This study aims to assess the cost-effectiveness of population strategy, i.e. mass screening, and Japan's health checkup reform.
methodsCost-effectiveness analysis was carried out to compare test modalities in the context of reforming Japan's mandatory annual health checkup for adults. A decision tree and Markov model with societal perspective were constructed to compare dipstick test to check proteinuria only, serum creatinine (Cr) assay only, or both.
resultsIncremental cost-effectiveness ratios (ICERs) of mass screening compared with do-nothing were calculated as ¥1,139,399/QALY (US $12,660/QALY) for dipstick test only, ¥8,122,492/QALY (US $90,250/QALY) for serum Cr assay only and ¥8,235,431/QALY (US $91,505/QALY) for both. ICERs associated with the reform were calculated as ¥9,325,663/QALY (US $103,618/QALY) for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥9,001,414/QALY (US $100,016/QALY) for mandating serum Cr assay and applying dipstick test at discretion.
conclusionsTaking a threshold to judge cost-effectiveness according to World Health Organization's recommendation, i.e. three times gross domestic product per capita of ¥11.5 million/QALY (US $128 thousand/QALY), a policy that mandates serum Cr assay is cost-effective. The choice of continuing the current policy which mandates dipstick test only is also cost-effective. Our results suggest that a population strategy for CKD detection such as mass screening using dipstick test and/or serum Cr assay can be justified as an efficient use of health care resources in a population with high prevalence of the disease such as in Japan and Asian countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.